191 related articles for article (PubMed ID: 37336103)
1. Recent advances in nitrogen-containing heterocyclic compounds as receptor tyrosine kinase inhibitors for the treatment of cancer: Biological activity and structural activity relationship.
Taruneshwar Jha K; Shome A; Chahat ; Chawla PA
Bioorg Chem; 2023 Sep; 138():106680. PubMed ID: 37336103
[TBL] [Abstract][Full Text] [Related]
2. Design, synthesis and biological evaluation of substituted pyrrolo[2,3-d]pyrimidines as multiple receptor tyrosine kinase inhibitors and antiangiogenic agents.
Gangjee A; Namjoshi OA; Yu J; Ihnat MA; Thorpe JE; Warnke LA
Bioorg Med Chem; 2008 May; 16(10):5514-28. PubMed ID: 18467105
[TBL] [Abstract][Full Text] [Related]
3. Splice Variants of the RTK Family: Their Role in Tumour Progression and Response to Targeted Therapy.
Abou-Fayçal C; Hatat AS; Gazzeri S; Eymin B
Int J Mol Sci; 2017 Feb; 18(2):. PubMed ID: 28208660
[TBL] [Abstract][Full Text] [Related]
4. Naphthalimides exhibit in vitro antiproliferative and antiangiogenic activities by inhibiting both topoisomerase II (topo II) and receptor tyrosine kinases (RTKs).
Wang X; Chen Z; Tong L; Tan S; Zhou W; Peng T; Han K; Ding J; Xie H; Xu Y
Eur J Med Chem; 2013 Jul; 65():477-86. PubMed ID: 23770449
[TBL] [Abstract][Full Text] [Related]
5. SU14813: a novel multiple receptor tyrosine kinase inhibitor with potent antiangiogenic and antitumor activity.
Patyna S; Laird AD; Mendel DB; O'farrell AM; Liang C; Guan H; Vojkovsky T; Vasile S; Wang X; Chen J; Grazzini M; Yang CY; Haznedar JO; Sukbuntherng J; Zhong WZ; Cherrington JM; Hu-Lowe D
Mol Cancer Ther; 2006 Jul; 5(7):1774-82. PubMed ID: 16891463
[TBL] [Abstract][Full Text] [Related]
6. Receptor tyrosine kinase inhibitors in cancer.
Ebrahimi N; Fardi E; Ghaderi H; Palizdar S; Khorram R; Vafadar R; Ghanaatian M; Rezaei-Tazangi F; Baziyar P; Ahmadi A; Hamblin MR; Aref AR
Cell Mol Life Sci; 2023 Mar; 80(4):104. PubMed ID: 36947256
[TBL] [Abstract][Full Text] [Related]
7. Quinazoline-based multi-tyrosine kinase inhibitors: synthesis, modeling, antitumor and antiangiogenic properties.
Conconi MT; Marzaro G; Urbani L; Zanusso I; Di Liddo R; Castagliuolo I; Brun P; Tonus F; Ferrarese A; Guiotto A; Chilin A
Eur J Med Chem; 2013 Sep; 67():373-83. PubMed ID: 23900004
[TBL] [Abstract][Full Text] [Related]
8. To Investigate Growth Factor Receptor Targets and Generate Cancer Targeting Inhibitors.
Basu D; Pal R; Sarkar M; Barma S; Halder S; Roy H; Nandi S; Samadder A
Curr Top Med Chem; 2023; 23(30):2877-2972. PubMed ID: 38164722
[TBL] [Abstract][Full Text] [Related]
9. Targeting receptor tyrosine kinases for chemoprevention by green tea catechin, EGCG.
Shimizu M; Shirakami Y; Moriwaki H
Int J Mol Sci; 2008 Jun; 9(6):1034-1049. PubMed ID: 19325845
[TBL] [Abstract][Full Text] [Related]
10. Phylogenetic and transcriptomic characterization of insulin and growth factor receptor tyrosine kinases in crustaceans.
Flores KA; Pérez-Moreno JL; Durica DS; Mykles DL
Front Endocrinol (Lausanne); 2024; 15():1379231. PubMed ID: 38638139
[TBL] [Abstract][Full Text] [Related]
11. Flavonoids as RTK inhibitors and potential anticancer agents.
Teillet F; Boumendjel A; Boutonnat J; Ronot X
Med Res Rev; 2008 Sep; 28(5):715-45. PubMed ID: 18080331
[TBL] [Abstract][Full Text] [Related]
12. How the structural properties of the indole derivatives are important in kinase targeted drug design?: A case study on tyrosine kinase inhibitors.
Mondal D; Amin SA; Moinul M; Das K; Jha T; Gayen S
Bioorg Med Chem; 2022 Jan; 53():116534. PubMed ID: 34864496
[TBL] [Abstract][Full Text] [Related]
13. Small-molecule inhibitors of the receptor tyrosine kinases: promising tools for targeted cancer therapies.
Hojjat-Farsangi M
Int J Mol Sci; 2014 Aug; 15(8):13768-801. PubMed ID: 25110867
[TBL] [Abstract][Full Text] [Related]
14. Effects of multi and selective targeted tyrosine kinase inhibitors on function and signaling of different bladder cancer cells.
Hänze J; Kessel F; Di Fazio P; Hofmann R; Hegele A
Biomed Pharmacother; 2018 Oct; 106():316-325. PubMed ID: 29966976
[TBL] [Abstract][Full Text] [Related]
15. Receptor Tyrosine Kinases: Translocation Partners in Hematopoietic Disorders.
Nelson KN; Peiris MN; Meyer AN; Siari A; Donoghue DJ
Trends Mol Med; 2017 Jan; 23(1):59-79. PubMed ID: 27988109
[TBL] [Abstract][Full Text] [Related]
16. Novel 5-substituted, 2,4-diaminofuro[2,3-d]pyrimidines as multireceptor tyrosine kinase and dihydrofolate reductase inhibitors with antiangiogenic and antitumor activity.
Gangjee A; Zeng Y; Ihnat M; Warnke LA; Green DW; Kisliuk RL; Lin FT
Bioorg Med Chem; 2005 Sep; 13(18):5475-91. PubMed ID: 16039863
[TBL] [Abstract][Full Text] [Related]
17. Targeting tumor micro-environment for design and development of novel anti-angiogenic agents arresting tumor growth.
Gacche RN; Meshram RJ
Prog Biophys Mol Biol; 2013 Nov; 113(2):333-54. PubMed ID: 24139944
[TBL] [Abstract][Full Text] [Related]
18. Imidazo[1,2-a]pyrazine diaryl ureas: inhibitors of the receptor tyrosine kinase EphB4.
Mitchell SA; Danca MD; Blomgren PA; Darrow JW; Currie KS; Kropf JE; Lee SH; Gallion SL; Xiong JM; Pippin DA; DeSimone RW; Brittelli DR; Eustice DC; Bourret A; Hill-Drzewi M; Maciejewski PM; Elkin LL
Bioorg Med Chem Lett; 2009 Dec; 19(24):6991-5. PubMed ID: 19879134
[TBL] [Abstract][Full Text] [Related]
19. Targeting Tyrosine kinases in Renal Cell Carcinoma: "New Bullets against Old Guys".
Alonso-Gordoa T; García-Bermejo ML; Grande E; Garrido P; Carrato A; Molina-Cerrillo J
Int J Mol Sci; 2019 Apr; 20(8):. PubMed ID: 30999623
[TBL] [Abstract][Full Text] [Related]
20. Role of receptor tyrosine kinases mediated signal transduction pathways in tumor growth and angiogenesis-New insight and futuristic vision.
Huang XL; Khan MI; Wang J; Ali R; Ali SW; Zahra QU; Kazmi A; Lolai A; Huang YL; Hussain A; Bilal M; Li F; Qiu B
Int J Biol Macromol; 2021 Jun; 180():739-752. PubMed ID: 33737188
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
